Challenges in modelling the cost effectiveness of various interventions for cardiovascular disease
- PMID: 24748448
- DOI: 10.1007/s40273-014-0155-9
Challenges in modelling the cost effectiveness of various interventions for cardiovascular disease
Abstract
Objectives: Decision analytic modelling is essential in performing cost-effectiveness analyses (CEAs) of interventions in cardiovascular disease (CVD). However, modelling inherently poses challenges that need to be dealt with since models always represent a simplification of reality. The aim of this study was to identify and explore the challenges in modelling CVD interventions.
Methods: A document analysis was performed of 40 model-based CEAs of CVD interventions published in high-impact journals. We analysed the systematically selected papers to identify challenges per type of intervention (test, non-drug, drug, disease management programme, and public health intervention), and a questionnaire was sent to the corresponding authors to obtain a more thorough overview. Ideas for possible solutions for the challenges were based on the papers, responses, modelling guidelines, and other sources.
Results: The systematic literature search identified 1,720 potentially relevant articles. Forty authors were identified after screening the most recent 294 papers. Besides the challenge of lack of data, the challenges encountered in the review suggest that it was difficult to obtain a sufficiently valid and accurate cost-effectiveness estimate, mainly due to lack of data or extrapolating from intermediate outcomes. Despite the low response rate of the questionnaire, it confirmed our results.
Conclusions: This combination of a review and a survey showed examples of CVD modelling challenges found in studies published in high-impact journals. Modelling guidelines do not provide sufficient guidance in resolving all challenges. Some of the reported challenges are specific to the type of intervention and disease, while some are independent of intervention and disease.
Similar articles
-
Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.Health Technol Assess. 2013 Dec;17(58):v-vi, 1-192. doi: 10.3310/hta17580. Health Technol Assess. 2013. PMID: 24325843 Free PMC article.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Are Current Reporting Standards Used to Describe Health State Utilities in Cost-Effectiveness Models Satisfactory?Value Health. 2020 Mar;23(3):397-405. doi: 10.1016/j.jval.2019.12.004. Epub 2020 Feb 15. Value Health. 2020. PMID: 32197736
-
Generalisability in economic evaluation studies in healthcare: a review and case studies.Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-192. doi: 10.3310/hta8490. Health Technol Assess. 2004. PMID: 15544708 Review.
-
How to develop cost-conscious guidelines.Health Technol Assess. 2001;5(16):1-69. doi: 10.3310/hta5160. Health Technol Assess. 2001. PMID: 11427188 Review.
Cited by
-
A cost-effectiveness analysis of a community based CVD program in Sweden based on a retrospective register cohort.BMC Public Health. 2018 Apr 4;18(1):452. doi: 10.1186/s12889-018-5339-3. BMC Public Health. 2018. PMID: 29618323 Free PMC article.
-
Using meta-regression analyses in addition to conventional systematic review methods to examine the variation in cost-effectiveness results - a case study.BMC Health Serv Res. 2016 Jan 20;16:23. doi: 10.1186/s12913-015-1230-4. BMC Health Serv Res. 2016. PMID: 26791941 Free PMC article.
-
Cost-benefit analysis of kidney transplant in patients with chronic kidney disease: a case study in Iran.Cost Eff Resour Alloc. 2022 Jul 29;20(1):37. doi: 10.1186/s12962-022-00372-1. Cost Eff Resour Alloc. 2022. PMID: 35906692 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources